USA - NASDAQ:VERV - US92539P1012 - Common Stock
Taking everything into account, VERV scores 3 out of 10 in our fundamental rating. VERV was compared to 534 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for VERV as it has an excellent financial health rating, but there are worries on the profitability. VERV is valued expensive and it does not seem to be growing.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -29.47% | ||
| ROE | -38.23% | ||
| ROIC | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.34 | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.84 | ||
| Quick Ratio | 9.84 | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A | 
11.13
+0.03 (+0.27%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 16.64 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.1 | ||
| P/tB | 2.1 | ||
| EV/EBITDA | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -29.47% | ||
| ROE | -38.23% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 66.21% | ||
| Cap/Sales | 7.59% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 9.84 | ||
| Quick Ratio | 9.84 | ||
| Altman-Z | 2.34 | 
ChartMill assigns a fundamental rating of 3 / 10 to VERV.
ChartMill assigns a valuation rating of 0 / 10 to VERVE THERAPEUTICS INC (VERV). This can be considered as Overvalued.
VERVE THERAPEUTICS INC (VERV) has a profitability rating of 1 / 10.